Phaseline

Companies › Vaxine

Vaxine: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tozinameran (CpG55)
Spike glycoprotein vaccine antigen
–Phase 1covid19 InfectionDec 2026
Radvax
Autologous tumor vaccine with polysaccharide adjuvant
–Phase 1Solid TumorFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06355232Tozinameran (CpG55)Phase 1covid19 InfectionInfectious diseaseDec 2026
NCT06355232Tozinameran (CpG55)Phase 1covid19 InfectionInfectious diseaseDec 2026
NCT05807035RadvaxPhase 1Solid TumorOncologyFeb 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.